Analyst Price Targets — GKOS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 12:18 pm | David Saxon | Needham | $127.00 | $106.64 | TheFly | Glaukos price target raised to $127 from $125 at Needham |
| February 18, 2026 11:25 am | — | Wells Fargo | $135.00 | $106.64 | TheFly | Glaukos price target raised to $135 from $122 at Wells Fargo |
| January 28, 2026 5:18 pm | — | BTIG | $131.00 | $125.46 | TheFly | Glaukos price target raised to $131 from $123 at BTIG |
| January 22, 2026 12:32 pm | — | Stifel Nicolaus | $160.00 | $124.16 | TheFly | Glaukos price target raised to $160 from $115 at Stifel |
| January 14, 2026 12:59 pm | — | Piper Sandler | $165.00 | $100.62 | StreetInsider | Piper Sandler on Glaukos Corporation (GKOS): 'Strong Q4 Print Overshadowed Some By iDose Buy-Side Bogey' |
| January 9, 2026 10:49 am | — | Goldman Sachs | $138.00 | $114.15 | TheFly | Glaukos price target raised to $138 from $112 at Goldman Sachs |
| January 2, 2026 12:08 pm | — | Stephens | $145.00 | $112.91 | TheFly | Glaukos price target raised to $145 from $115 at Stephens |
| December 23, 2025 12:04 pm | — | UBS | $145.00 | $117.09 | TheFly | Glaukos price target raised to $145 from $140 at UBS |
| December 18, 2025 2:10 pm | — | Truist Financial | $145.00 | $115.85 | TheFly | Glaukos price target raised to $145 from $120 at Truist |
| December 17, 2025 12:02 pm | — | UBS | $165.00 | $113.76 | StreetInsider | Piper Sandler on Glaukos Corporation (GKOS): 'Our 2026 Top Idea' |
Latest News for GKOS
GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities.…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release first quarter 2026 financial results after the market close on Wednesday, April 29, 2026. The company's management will discuss the results during a conference call and…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for GKOS.
U.S. House Trading
No House trades found for GKOS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.